Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score-Matched Analysis.

INTRODUCTION The optimal duration and clinical benefit of neoadjuvant gemcitabine plus nab-paclitaxel (GnP) for resectable pancreatic cancer (RPC) remain uncertain. METHODS We conducted a prospective single-arm phase II study evaluating neoadjuvant GnP in RPC. The primary end point was 2-y relapse-free survival (RFS)...

K. Ishido, N. Kimura, H. Nagase et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.